Jpmorgan Chase & CO Ambrx Biopharma Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023
BUY
$7.66 - $16.46 $1.21 Million - $2.6 Million
157,858 New
157,858 $2.6 Million

Others Institutions Holding AMAM

# of Institutions
2
Shares Held
31.2K
Call Options Held
0
Put Options Held
0
View Full List

About Ambrx Biopharma Inc.

AMAM Quotes by TradingView
  • Ticker AMAM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,618,400
  • Market Cap $1.08B
  • Description
  • Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...
More about AMAM
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email